NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) announced the Committee
for Medicinal Products for Human Use or CHMP of the European Medicines Agency
has recommended approval of Opdivo in combination with cisplatin and gemcitabine
for the first-line treatment of adult patients with unresectable or metastatic
urothelial carcinoma. The positive CHMP opinion is based on results from a
sub-study of the CheckMate -901 trial. The European Commission will review the
CHMP recommendation. The final EC decision is anticipated in June 2024.

On March 7, 2024 the FDA approved the use of Opdivo in combination with
cisplatin and gemcitabine as a first-line treatment for adult patients with
unresectable or metastatic urothelial carcinoma, following a Priority Review.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX